Floatz logo

Cetuximab

Oropharynx Squamous Cell Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Oropharynx Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
e7 tcr-t cells
Christian Hinrichs
Phase 2B
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Regeneron Pharmaceuticals
Phase 2CCC
Cabozantinib
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC

View all 31 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
rectal carcinomaActive
BB
Indicative · Phase 2
69 / 100
View asset →
non-small cell lung carcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →